119P Efficacy and safety profile of eribulin mesylate in advanced breast cancer: Single-centre experience from India

Abstract

Background: Patients with advanced breast cancer are usually resistant to anthracyclines and taxanes. Treatment failure is observed in majority of metastatic breast cancer patients and 5 year survival rate is only 27%. Treatment guidelines do not recommend any single agent or a combination regimen in particular sequence for advanced breast cancer. Eribulin mesylate a microtubule polymerization inhibitor is the first single agent chemotherapy with proven overall survival benefit and tolerable safety profile in advanced breast cancer patients. Methods: This is a retrospective analysis of 23 advanced breast cancer patients irrespective of hormone or HER2 receptor status. These patients were treated previously with anthracycline and/or taxanes and at least one chemotherapy for advanced disease. 1.4 mg/m2 eribulin mesylate was administered on day 1 and 8 of 21 days cycle until disease progression or occurrence of an unacceptable toxicity, or the patient not willing to continue the treatment. Results: Out of 23 patients analyzed, 11 patients responded to eribulin mesylate. Patients received average 4 cycles of eribulin mesylate. The objective response rate was 34.7% and clinical benefit rate was 47.8%. 8 patients had partial response. 4 patients even in 4th line of chemotherapy responded optimally to eribulin. Response rates were consistent in all patient subgroups. Neutropenia was the commonest reported adverse event (13%) followed by peripheral neuropathy (8.7%). Two patients reported grade 3 neutropenia and two patients reported grade 2/3 neuropathy. Disease progression was the most common reason for discontinuation of treatment with eribulin mesylate. Conclusions: Our single centre experience shows clinical outcomes similar to phase III clinical trials of eribulin mesylate and real world data mentioned in literature.